We serve Chemical Name:2-(4-chloro-3,5-dimethylphenoxy)acetic acid CAS:19545-95-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(4-chloro-3,5-dimethylphenoxy)acetic acid
CAS.NO:19545-95-0
Synonyms:4-chloro-3,5-xylyloxyacetic acid
Molecular Formula:C10H11ClO3
Molecular Weight:214.64600
HS Code:2918990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:345.1ºC at 760mmHg
Density:1.269g/cm3
Index of Refraction:1.547
PSA:46.53000
Exact Mass:214.04000
LogP:2.42020
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-chloro-3,5-xylyloxyacetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-chloro-3,5-xylyloxyacetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-chloro-3,5-xylyloxyacetic acid Use and application,4-chloro-3,5-xylyloxyacetic acid technical grade,usp/ep/jp grade.
Related News: Bluebird also earned an approval Wednesday in Europe for its gene therapy Lenti-D for children with early cerebral adrenoleukodystrophy and an ABCD1 genetic mutation without a matched sibling donor. 2-Bromo-5-methylpyrazine manufacturers “Partnering with a CDMO that has the skills and capabilities to execute a successful tech transfer is critical, as this complex, multi-step process helps lay the foundation for the new drug’s journey through to commercialization. 4-tert-Butylcyclohexyl acetic acid suppliers The factory is part of a partnership with Nichepharm Lifesciences of India. Recipharm has an 8% stake in that company after an investment two years ago. 7-(dimethylamino)-4-methyl-1H-quinolin-2-one vendor & factory The factory is part of a partnership with Nichepharm Lifesciences of India. Recipharm has an 8% stake in that company after an investment two years ago.,Biogen’s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug.
